Skip to content

Take5Care+: A Self-management Educational Intervention

Take5Care+: A Self-management Educational Intervention to Support the Haematology Patients' Journey Following a Neoplastic Diagnosis.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07674212
Acronym
Take5Care+
Enrollment
20
Registered
2026-06-29
Start date
2026-07-01
Completion date
2027-10-01
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic Neoplasms

Keywords

hematologic neoplasms, pilot intervention, feasibility study

Brief summary

Patients who are diagnosed with haematological malignancies may feel that they have little or no control over their health which can be distressing. However, a diagnosis can also be the opportunity for a "teachable moment" during which patients are more likely to open to behaviour change, which can positively impact on their health and wellbeing. Take Five to Age Well (Take Five) was designed to empower people to achieve effective, long-term self-management of health by introducing healthy habits in 30 days. In collaboration with Northampton General Hospital (NGH) the current study will recruit newly diagnosed haematology patients who are either being actively monitored or only on non-intensive treatment to take part in a self-managed behaviour change intervention. This is primarily a feasibility study to inform main trials in the future. The main aim of the research is: 1. To assess the feasibility of using Take5Care+ with patients newly diagnosed with indolent or chronic haematological malignancies, recruited via hospital departments There are also secondary aims, including: 2. To assess the impact of participating in Take5Care+ on patients' self-reported health and well-being, healthy behaviours and sense of control, knowledge and management of health 3. To explore the perceptions of patients and clinicians about their participation in the Take5Care+ Patients who wish to take part will be asked to fill out a survey at baseline, complete a "challenge" where they commit to a healthy action for 30 days, fill out a second survey immediately after and a third survey three months later. Patients may also consent to participating in an interview post-challenge. Giving consent and completing the baseline survey will take place in NGH but the challenge is self-managed at home and remotely supported. Survey 2, Survey 3 and the optional interviews are also carried out online or over the phone.

Interventions

OTHERTake5Care+

Newly diagnosed haematology patients will be recruited to take part in a self-managed behaviour change intervention. Participants commit to a behavioural action (a "healthy habit") from a predetermined list for 30 days.

Sponsors

Jitka Vseteckova
Lead SponsorOTHER
Northampton General Hospital NHS Trust
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years or older. * Have been diagnosed within the last 3 months with one of the eligible conditions listed in Table 1. * Be managed with either: * Active monitoring, or * Non-intensive oral therapy, defined as outpatient oral regimens that do not require inpatient initiation and have lower expected toxicity (e.g., BTK inhibitors, TKIs, interferon, lenalidomide, hydroxycarbamide, low-dose alkylators). * Have ECOG Performance Status 0-2. * Be able to give informed consent. * Be judged suitable for participation by the treating clinician.

Exclusion criteria

* Receiving intensive chemotherapy, immunotherapy, IV combination regimens, cellular therapy, radiotherapy or treatments requiring inpatient initiation. * Received or expected to require regular blood product transfusions * Life expectancy \<12 months. * Acutely terminal illness. * ECOG ≥3. * Cognitive impairment that would prevent the patient from giving informed consent, or reliably completing the daily action and follow-up assessments * Pregnant or lactating. * Currently participating in a CTIMP or other behavioural research intervention. * Age \<18. * Unstable, uncontrolled, or severe comorbidities: * Uncontrolled heart failure, unstable angina, or MI \<3 months. * Stroke/TIA \<3 months. * Severe/unstable COPD or asthma with recent exacerbations. * Poorly controlled diabetes * Severe psychiatric illness interfering with participation. * Concurrent active malignancy requiring systemic therapy. * Any other condition that, in the investigator's judgement, would compromise safe participation.

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of the interventionFrom beginning of study (0 weeks) until data collection is completed (up to 10 months)* % of patients who are recruited from possible participant pool (anonymous) during recruitment period (recruitment numbers = number of participants/number of total participants) * % of patients who withdraw from study via study log (study attrition = number of withdrawals/number of total participants who consent into study) * % of patients who withdraw from survey during survey completion (survey attrition = number of incomplete surveys/number of times survey is started) All data is secondary data and will not require participant input.
Qualitative exploration of feasibility of studyDirectly after participant completes the intervention (at 4 weeks)* Optional semi-structured interviews with participants, analysed using thematic analysis * Qualitative interviews with healthcare professionals, analysed using thematic analysis

Secondary

MeasureTime frameDescription
Self-reported behaviours of healthy behaviourSurvey 1 will be at 0 weeks, survey 2 will be at 4 weeks and survey 3 will be at 16 weeks• Self-reported behaviours that facilitate improved nutrition, hydration, physical activity, cognitive stimulation and social engagement using a 7-point Likert scale ranging from "Never" to "Every day", collected at Survey 1, Survey 2 and Survey 3.
Self-reported healthSurvey 1 will be at 0 weeks, survey 2 will be at 4 weeks and survey 3 will be at 16 weeks• Self-reported health as measured by SF-12, transformed into two scores: * Physical component summary score ranging from 0 - 100 * Mental component summary score ranging from 0 - 100 The measures will be collected at Survey 1, Survey 2 and Survey 3.
Self-reported adherence to Take5Care+ actionsSurvey 2 will be at 4 weeks and Survey 3 at 16 weeks.• Participants will be asked how many days a week, on average, they are still doing their chosen action, from 1-7 days. This data will be collected at Survey 2 and Survey 3.
Subjective perception of healthSurvey 1 will be at 0 weeks, survey 2 will be at 4 weeks and survey 3 will be at 16 weeks* Perceived control over health * Perceived knowledge of how to maintain health * Perceived ability to manage health Participants will be asked to rate themselves on statements relating to the concept above on a 7-point Likert scale ranging from "Strongly disagree" to "Strongly agree".
Explore perceptions of patients and cliniciansDirectly after the intervention (at 4 weeks)Thematic analysis of perceptions of participation, barriers and facilitators via semi-structured interviews with patients (optional) and clinicians

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 30, 2026